This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Niemann-Pick disease — NPA/NPB: SMPD1/acid sphingomyelinase; NPC: NPC1/NPC2 / sphingomyelin lipidosis니만-픽병 (스핑고미엘린 리피도시스)

Contents and key points
ItemDetails
A. Classification codesICD-10: E75.2 (other sphingolipidosis) | Special Copayment Reduction: V117 (ultra-rare disease)
B. SynonymsNiemann-Pick disease, Niemann-Pick disease types A/B/C, sphingomyelin lipidosis, acid sphingomyelinase deficiency (NPA/B: SMPD1 deficiency), Niemann-Pick type C (NPC1/NPC2 deficiency, lipid trafficking disorder)
C. Adult onsetLikelihood of first onset in adulthood present (types NPB and NPC) — NP-A is an infantile form with no adult onset. NP-B patients survive into adulthood with mainly visceral symptoms and are sometimes first diagnosed in adulthood. In the adult form of NP-C, diagnosis is often made after decades of misdiagnosis, with psychosis, dementia, movement disorders, and vertical gaze palsy.
1. History1914 Niemann describes an infantile lipid storage disease → 1922 Pick describes hepatosplenomegaly and neurodegeneration → 1961 acid sphingomyelinase deficiency confirmed → 1973 Brady, separate classification of NPC → 1997 NPC1 gene identified → 2000 NPC2 gene identified → 2009 miglustat (NPC treatment) approved → 2022 olipudase alfa (NPB) FDA approved.
2. CausesNPA/B: SMPD1 gene variants → acid sphingomyelinase (ASM) deficiency → lysosomal accumulation of sphingomyelin and cholesterol. NPC: NPC1 (95%) or NPC2 (5%) gene variants → impaired trafficking of unesterified cholesterol and sphingomyelin within lysosomes and endosomes.
3. GeneticsAll autosomal recessive. SMPD1 (11p15.4): NPA/B. NPC1 (18q11.2): 95% of NPC. NPC2 (14q24.3): 5% of NPC. NPA founder variant in Ashkenazi Jews (p.Arg496Leu). NPC has diverse variants, >500.
4. General epidemiologyNPA/B: about 1 in 250,000 births (NPA high in Ashkenazi Jews). NPC: about 1 in 120,000–150,000 births. Occurs in all ethnicities. Cases have been reported in Korea.
5. PathophysiologyNPA/B: ASM deficiency → intralysosomal accumulation of sphingomyelin → death of neural (NPA) and visceral (NPA/B) cells. NPC: NPC1/NPC2 deficiency → blocked transport of unesterified cholesterol within lysosomes → secondary accumulation of cholesterol, sphingomyelin, and gangliosides in brain and visceral cells → neuronal death.
6. SymptomsNPA: rapid neurodegeneration in infancy, hepatomegaly, cherry-red spot. NPB: mainly visceral (hepatosplenomegaly, pulmonary involvement), mild neurological symptoms. NPC: hepatomegaly (infancy/neonatal period) → vertical and horizontal gaze palsy (VSGP), cerebellar ataxia, cognitive regression, epilepsy, hypersomnia, dystonia, psychosis in the adult form.
7. SignsNPA: cherry-red spot (macula). NPB: hepatosplenomegaly, pulmonary interstitial lesions. NPC: vertical gaze palsy (VSGP) — highly specific, triggered cataplexy, hepatosplenomegaly. Bone marrow biopsy: foamy histiocytes (foamy macrophages).
8. ScreeningNPA/B: ASM enzyme activity in DBS (newborn screening research). NPC: measurement of plasma oxysterols (24S-OHC, 25-OHC) or lyso-SM-509 as highly sensitive screening biomarkers. Carrier screening for the NPA founder variant in Ashkenazi Jews.
9. DiagnosisNPA/B: reduced ASM activity (leukocytes, plasma) + SMPD1 variants. NPC: filipin staining (fluorescent cholesterol accumulation, fibroblasts) + NPC1/2 gene analysis. Elevated plasma oxysterols. Bone marrow or liver biopsy: foamy histiocytes.
10. TreatmentNPA: no curative treatment (symptomatic). NPB: olipudase alfa (Xenpozyme, ERT, FDA approved 2022), miglustat. NPC: miglustat (substrate reduction therapy, approved EU 2009/FDA 2023), arimoclomol (clinical trials ended), symptomatic treatment.
11. PrognosisNPA: most die by age 3–5 (brain involvement). NPB: survival into adulthood possible, with life expectancy shortened by pulmonary and hepatic complications. NPC: varies with age of onset; the adult form may survive for decades but with progressive disability. Miglustat partly delays neurodegeneration.
12. PreventionCarrier testing, genetic counseling, prenatal diagnosis. Screening for the NPA founder variant in the Ashkenazi Jewish population. Delaying neurodegeneration in NPC through early diagnosis and early start of miglustat.
13. ReferencesNiemann A. 1914; Pick L. 1922 and 9 other references

1. History

Niemann-Pick disease became known in 1914 when the German pediatrician Albert Niemann reported a Jewish infant who showed severe neurodegeneration and hepatosplenomegaly and died at 18 months. This patient was described at the time as having "a peculiar disease of the fat exchange process" and showed features clinically similar to yet distinct from Gaucher disease. In 1922 the German internist Ludwig Pick reported 4 additional patients with similar clinical features and described the syndrome in detail, after which it was named "Niemann-Pick disease" after the two researchers.

The first advance in the molecular mechanism came in 1961. Crawford et al., followed by the team of Roscoe Brady, discovered deficient acid sphingomyelinase (ASM) activity in liver tissue from patients with Niemann-Pick disease (as it was then collectively called), and the main accumulated substrate was confirmed to be sphingomyelin. With this, patients corresponding to the present NP-A and NP-B types were confirmed on a molecular basis.

However, it was gradually recognized that some patients clinically classified as having Niemann-Pick disease had normal ASM activity and thus a separate disease. From 1958 onward, this separate disease group came to be called "Niemann-Pick type C (NPC)". The molecular basis of NPC was revealed much later. In 1997 Patterson et al. and Carstea et al. identified the NPC1 gene (18q11.2), and in 2000 the NPC2 gene (14q24.3) was additionally identified. As it was revealed that these two gene products (the NPC1 membrane protein and the NPC2 soluble protein) transport unesterified cholesterol (free cholesterol) in lysosomes/late endosomes, NPC was redefined as a disorder of lysosomal cholesterol trafficking rather than a classic lysosomal hydrolase deficiency.

In terms of treatment, there is still no disease-modifying therapy for type NP-A, whereas for type NP-B the first ERT was introduced when the FDA approved the recombinant ASM olipudase alfa (Xenpozyme, Sanofi) in 2022. For type NP-C, miglustat (Zavesca) was approved in Europe in 2009 to slow the progression of neurological symptoms, and in 2023 the FDA also approved it for neurological symptoms of NPC in pediatric and adult patients. A clinical trial of arimoclomol was terminated in 2021 after failing to demonstrate a significant effect in phase 3. Clinical studies of AAV gene therapy and cerebrospinal fluid administration of hydroxypropyl-β-cyclodextrin (HPβCD) are currently under way.


2. Causes

Niemann-Pick disease is divided into two categories with different molecular mechanisms.

Types NP-A and NP-B (acid sphingomyelinase deficiency): caused by biallelic variants in the SMPD1 gene (11p15.4), resulting in deficient activity of lysosomal acid sphingomyelinase (ASM, EC 3.1.4.12). ASM is the enzyme that hydrolyzes sphingomyelin into ceramide and phosphocholine within the lysosome. In ASM deficiency, sphingomyelin accumulates in the lysosomes of various cells, including monocytes, macrophages and neurons. Sphingomyelin, the main accumulated substrate, causes cellular dysfunction in the liver, spleen, lungs, brain and bone marrow. In type NP-A, residual ASM activity is almost absent (less than 1%) and neurological involvement is severe, whereas in type NP-B some residual activity is preserved (5~10%) and neurological involvement is mild or absent.

Type NP-C (lysosomal cholesterol trafficking disorder): caused by biallelic variants in the NPC1 gene (18q11.2, about 95% of all NPC) or the NPC2 gene (14q24.3, about 5%). NPC1 is a 13-transmembrane protein of the lysosomal membrane, located at the limiting membrane of late endosomes and lysosomes, and is responsible for transporting unesterified cholesterol (free cholesterol). NPC2 is a small soluble protein secreted into the lysosomal lumen that delivers membrane cholesterol to NPC1. Loss of function of either protein leads to abnormal accumulation of unesterified cholesterol in lysosomes and late endosomes, with secondary accumulation of sphingomyelin and gangliosides (GM2, GM3). Unlike NPA/B caused by SMPD1 deficiency, ASM activity is normal.


3. Genetics

The SMPD1 gene is located on the short arm of chromosome 11 (11p15.4) and consists of 6 exons. The translated precursor protein is 629 amino acids long, and after signal peptide cleavage the mature ASM is secreted into the lysosome. More than about 180 pathogenic SMPD1 variants have been reported to date. In Ashkenazi Jews, p.Arg496Leu (R496L) and L302P are known as founder variants associated with NPA, and the carrier rate in this population is high, at about 1/80~1/100. Variants associated with type NP-B are diverse, with little concentration in particular populations.

The NPC1 gene is located on the long arm of chromosome 18 (18q11.2) and consists of 25 exons. The translated protein is 1,278 amino acids long and has 13 transmembrane domains and a sterol-sensing domain (SSD). More than 500 pathogenic NPC1 variants have been reported to date, with missense variants being the most common. In particular, p.Ile1061Thr is known as the most common NPC1 variant, found in about 15~25% of patients of European descent. The NPC2 gene is located on the long arm of chromosome 14 (14q24.3) and consists of 5 exons. The NPC2 protein is a small soluble protein of 131 amino acids and is identical to HE1 (human epididymis protein 1).

All types of Niemann-Pick disease follow an autosomal recessive mode of inheritance. Carriers are usually asymptomatic, although cases of mild visceromegaly in some female carriers of type NP-B have been reported. The recurrence risk for siblings is 25% with each pregnancy. Phenotype-genotype correlation is partly clear for NPC1: p.Ile1061Thr homozygotes are associated with the juvenile/adult-onset forms, and other severe loss-of-function variants are associated with the infantile/childhood-onset forms.


4. General epidemiology

Types NP-A and NP-B: the overall incidence of types NP-A/B due to SMPD1 deficiency is estimated at about 1 in 250,000 births worldwide. In Ashkenazi Jews, the incidence of type NP-A is high, at about 1 in 40,000 births, reflecting a founder effect. Type NP-B occurs worldwide without ethnic predilection, and there are reports of a relatively higher frequency in patients of North African origin. By clinical type, type NP-A accounts for about 40~50% and type NP-B for 50~60% of the total.

Type NP-C: traditional clinically based estimates are about 1 in 120,000~150,000 births, but recent estimates based on molecular diagnosis and oxysterol biomarker screening suggest a much higher figure of about 1 in 40,000~50,000 births. It occurs in all ethnic groups worldwide, with little predilection for particular ethnicities. Clusters of founder variants have been reported in certain regions (the Canary Islands, Nova Scotia, etc.).

In Korea there are no accurate epidemiological data for Niemann-Pick disease as a whole, but the estimated number of patients based on health insurance claims data is in the range of tens to hundreds, and it is designated as an ultra-rare disease (Special Copayment Reduction V117). Because of low diagnostic awareness, the proportion of undiagnosed patients is thought to be high, particularly for adult-onset NPC.


5. Pathophysiology

Pathophysiology of types NP-A and NP-B: owing to ASM deficiency, sphingomyelin accumulates in the lysosomes of various cells, including monocytes/macrophages, hepatocytes, pulmonary macrophages and neurons. Sphingomyelin overload causes lysosomal dysfunction, mitochondrial dysfunction and increased apoptosis. In type NP-A, with severe brain involvement, sphingomyelin accumulation in neuronal lysosomes leads to synaptic dysfunction, abnormal dendrite formation and neuronal death. Accumulation in retinal ganglion cells produces the cherry-red spot. In type NP-B, brain involvement is mild, and foam cells form mainly in the mononuclear phagocyte system of the liver, spleen, lungs and bone marrow, causing hepatosplenomegaly, liver fibrosis and reduced lung function.

Pathophysiology of type NP-C: loss of NPC1/NPC2 function traps unesterified cholesterol in late endosomes and lysosomes. The normal pathway, in which NPC2 delivers cholesterol to NPC1 and NPC1 transports it out across the lysosomal membrane to the endoplasmic reticulum (ER) and plasma membrane, is blocked. The block in cholesterol transport causes disturbances of plasma membrane cholesterol homeostasis, dysregulation of fatty acid synthesis, abnormal ceramide production and other abnormalities. Secondarily, sphingomyelin and GM2 and GM3 gangliosides also accumulate in brain neurons. In the brain, cerebellar Purkinje cells and cerebral cortical neurons are particularly and selectively vulnerable and are progressively lost. Cerebellar atrophy and neocortical neurodegeneration are the main anatomical basis of the neurological symptoms of NPC. Involvement of the pontine nuclei and superior colliculus of the brainstem is the cause of vertical supranuclear gaze palsy (VSGP).

Tau protein hyperphosphorylation (formation of neurofibrillary tangles) and abnormal processing of amyloid precursor protein have also been reported in NPC, drawing attention to its pathological similarity to Alzheimer disease. Indeed, because abnormal cholesterol transport is also linked to the pathogenesis of Alzheimer disease, NPC research is also contributing to the understanding of Alzheimer pathophysiology.


6. Symptoms

The clinical symptoms of Niemann-Pick disease differ greatly by type.

Type NP-A (acute infantile form): begins at 3~6 months of age with hepatosplenomegaly and developmental arrest/regression and progresses rapidly. A cherry-red spot is observed in about 50%. Hypotonia, developmental regression and loss of vision appear before 1 year of age, followed by dysphagia and respiratory failure. Most patients die at 2~4 years of age. Pulmonary involvement (accumulation of sphingomyelin in alveolar macrophages) leads to recurrent pneumonia.

Type NP-B (chronic visceral form): visceral involvement is the predominant feature. Hepatomegaly and splenomegaly begin in infancy to childhood, and thrombocytopenia and anemia due to splenomegaly appear. Liver fibrosis progresses and can lead to portal hypertension and cirrhosis. Pulmonary involvement causes interstitial lung disease, chronic hypoxemia due to accumulation in alveolar macrophages, and respiratory failure. Neurological symptoms are mild (peripheral neuropathy, mild intellectual impairment) or absent. Survival into adulthood is possible, and the disease is sometimes first diagnosed in adulthood.

Type NP-C: broadly classified into five periods according to age of onset.


7. Signs

Signs of type NP-A: a cherry-red spot is seen on funduscopy in about 50% (a mechanism similar to GM1/GM2 gangliosidosis). Hypotonia, a shift from hyperreflexia to hyporeflexia, and generalized weakness progress. Marked hepatosplenomegaly on abdominal palpation. Crackles are heard on lung auscultation when there is interstitial lung involvement.

Signs of type NP-B: hepatosplenomegaly is the most prominent sign. The enlarged spleen may be palpable down to the right lower abdomen. Chest radiographs show interstitial lung opacities and a pulmonary infiltrate pattern. High-resolution CT (HRCT) shows basal-predominant ground-glass opacity and a reticular pattern. Blood tests show thrombocytopenia, anemia and elevated liver enzymes.

The most specific sign of type NP-C: Vertical Supranuclear Gaze Palsy (VSGP): the most diagnostically important neurological sign of NPC. Paralysis or limitation of voluntary vertical eye movements—especially downgaze—is characteristic, and preservation of eye movements on the oculocephalic reflex (doll's eye maneuver) confirms a supranuclear lesion. It begins with slowing of vertical saccades and progresses to complete paralysis. VSGP appears at some point in more than about 90% of NPC patients and is a highly valuable diagnostic clue. However, it may not be observed early, so periodic reassessment is needed.

Gelastic cataplexy: a phenomenon in which sudden loss of muscle tone is triggered by laughter or emotional stimuli, characteristically observed in NPC. It presents as knee buckling, relaxation of facial muscles and similar features.

Bone marrow findings: foam cells (foamy macrophages or sea-blue histiocytes) are seen on bone marrow aspiration or biopsy. These are macrophages laden with sphingomyelin; they were formerly a diagnostic criterion but are now used as a supportive finding.

Plasma oxysterols and lyso-SM-509: plasma oxysterols such as 24S-hydroxycholesterol (24S-OHC), 25-hydroxycholesterol (25-OHC) and 7-ketocholesterol, as well as lyso-sphingomyelin-509 (lyso-SM-509), are markedly elevated in NPC patients and are used as highly sensitive and highly specific biochemical diagnostic biomarkers.


8. Screening

Screening for types NP-A/B: a newborn screening method measuring ASM enzyme activity in DBS has been technically developed but is not included in the standard newborn screening panel in most countries. In the Ashkenazi Jewish population, carrier screening for the type NP-A founder variants (p.Arg496Leu, p.Leu302Pro) is included in the Jewish genetic disease panel. Clinically, ASM activity measurement and SMPD1 gene analysis are performed selectively in patients with hepatosplenomegaly and pulmonary infiltrates and in patients suspected of having a storage disease.

Screening for type NP-C: the most promising approach to reducing diagnostic delay in NPC is measurement of plasma oxysterols. LC-MS/MS measurement of plasma 24S-OHC, 25-OHC, 7-ketocholesterol or lyso-SM-509 shows high sensitivity and specificity in NPC patients. In particular, NPC should be actively suspected and oxysterols measured in patients hospitalized for neonatal jaundice, infants with unexplained hepatosplenomegaly, and patients with unexplained cerebellar ataxia, psychosis or cognitive decline. Some institutions use the "NPC Suspicion Index" to screen high-risk patients systematically.


9. Diagnosis

Diagnosis of types NP-A and NP-B: a marked reduction in ASM activity in leukocytes or plasma (less than 5~10% of normal) is strongly suggestive. The diagnosis is confirmed by identifying biallelic pathogenic variants on NGS or Sanger analysis of the SMPD1 gene. Observation of foam cells on bone biopsy or bone marrow smear supports the diagnosis. In NP-A, the cherry-red spot and neurological symptoms provide additional diagnostic evidence.

Diagnosis of type NP-C: formerly, filipin staining after culture of skin fibroblasts—which visualizes lysosomal cholesterol accumulation based on filipin forming a fluorescent complex with unesterified cholesterol—was the diagnostic standard. Now, in addition to or instead of this method, measurement of plasma oxysterols (24S-OHC, 25-OHC, lyso-SM-509) is performed first as a highly sensitive biochemical screen, followed by NPC1/NPC2 gene analysis for confirmation. Even with NPC1 gene variants, filipin staining may show a normal or intermediate (atypical) pattern, so gene analysis is essential. The same diagnostic principles apply to NPC2 deficiency. Brain MRI shows cerebellar atrophy, white matter abnormalities and brainstem atrophy.


10. Treatment

Type NP-A: there is currently no disease-modifying treatment. Symptomatic and supportive care (seizure control, respiratory management, nutritional support) is the mainstay. Hematopoietic stem cell transplantation is at the research stage but is ineffective once neurological involvement has progressed. AAV-based SMPD1 gene therapy is being explored at the preclinical stage.

Type NP-B — olipudase alfa (Xenpozyme, ERT): recombinant human ASM (olipudase alfa) is the first ERT, approved by the FDA in August 2022 for pediatric and adult type NP-B. Biweekly intravenous administration reduces sphingomyelin accumulation in the liver, spleen, lungs and bone marrow, with demonstrated effects of reduced hepatosplenomegaly, improved lung function, normalization of platelet counts and reduced hepatic steatosis (ASCEND clinical trial). It is most suitable for type NP-B without central nervous system involvement. Treatment is started with dose escalation, and attention must be paid to infusion reactions.

Type NP-C — miglustat (Zavesca): an oral iminosugar intended as substrate reduction therapy through inhibition of glucosylceramide synthase. In NPC, it has been shown to slow the progression of neurodegeneration by inhibiting the secondary accumulation of gangliosides (GM2, GM3). It was approved in the EU in 2009 for stabilization of neurological symptoms of NPC, and in 2023 the FDA also approved it for pediatric and adult NPC. Adult dose: 200 mg orally 3 times daily. The main adverse effects are diarrhea, weight loss and peripheral neuropathy, and a low-carbohydrate diet can partly relieve the diarrhea. The greatest clinical effect is stabilization of eye movements, swallowing function and cognitive function; recovery of functions already lost is unlikely. Therefore early diagnosis and early initiation of treatment are important.

Adjunctive and supportive treatment of NPC: anticonvulsants are used for seizures, dietary modification and gastrostomy tubes for dysphagia, hypnotics or melatonin for sleep disturbance, antipsychotics for psychiatric symptoms (used with caution with an understanding of NPC mechanisms), and physical therapy and assistive devices for cerebellar ataxia. Clomipramine or SSRIs are tried for gelastic cataplexy. Clinical trials of cerebrospinal fluid administration of hydroxypropyl-β-cyclodextrin (HPβCD) are under way, aiming at a strategy of directly solubilizing cholesterol and extracting it from endosomes.


11. Prognosis

Type NP-A: the prognosis is extremely poor. Developmental regression becomes complete by 1~2 years of age, and most patients die of pneumonia or respiratory failure at 2~4 years of age. The course is one of rapidly progressive neurological symptoms following hepatosplenomegaly in infancy.

Type NP-B: when neurological involvement is absent or mild, survival into adulthood is possible, and many patients are first diagnosed in adulthood. The main prognostic factors are the extent of pulmonary involvement and the progression of liver fibrosis. Since the introduction of olipudase alfa ERT, preservation of lung function and inhibition of the progression of visceral involvement are expected. Even without treatment, life expectancy is shorter than that of the general population because of complications of declining lung function and cirrhosis.

Type NP-C: age of onset is the most important determinant of prognosis. In the infantile-onset form, neurological involvement is rapid and mortality before age 5 is high. In the childhood-onset form, the disease progresses over 5~15 years after the onset of neurological symptoms, and dysphagia and aspiration pneumonia are the terminal causes of death. In the adult form, survival of 10~20 years or more after the onset of neurological symptoms is possible, and miglustat treatment significantly delays the progression of neurological symptoms in some patients. Early initiation of miglustat (immediately after the onset of neurological symptoms) is more effective than late initiation. Adult NPC is frequently misdiagnosed as Alzheimer disease, schizophrenia, MSA and so on, and many cases with a delay of more than 10 years to diagnosis have been reported in the literature.


12. Prevention

Prevention of Niemann-Pick disease differs somewhat by type, but carrier testing, genetic counseling and prenatal diagnosis are central to all types.

Genetic counseling and carrier testing: for all types, once a patient is confirmed, genetic counseling and carrier testing are recommended for siblings and parents. In the Ashkenazi Jewish population, carrier screening for the type NP-A founder variants (p.Arg496Leu, p.Leu302Pro) is included in the standard Jewish genetic disease panel, and carrier couples are offered preconception genetic counseling and prenatal diagnosis options.

Prenatal diagnosis: for types NP-A/B, prenatal diagnosis is possible by measuring ASM activity and/or directly detecting SMPD1 variants in fetal cells from CVS or amniocentesis. For type NP-C, prenatal diagnosis is possible by filipin staining or NPC1/2 gene analysis of fetal cells. Preimplantation genetic testing (PGT-M) can also prevent implantation of affected embryos.

Preventing complications through early diagnosis of NPC: because early initiation of miglustat in NPC (in the early stage of neurological symptoms) is most effective in slowing the rate of neurodegeneration, early diagnosis is itself the key to preventing neurological damage. The best preventive approach is to include NPC in the differential diagnosis of infants with jaundice, children with unexplained hepatosplenomegaly and adults with unexplained neuropsychiatric symptoms, to confirm it rapidly by oxysterol testing and gene analysis, and to start miglustat early.


13. References

  1. Niemann A. Ein unbekanntes Krankheitsbild. Jahrbuch Kinderheilkunde. 1914;79:1-10.
  2. Brady RO, Kanfer JN, Mock MB, Fredrickson DS. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci USA. 1966;55(2):366-369. PMID: 5220952.
  3. Carstea ED, Morris JA, Coleman KG, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997;277(5323):228-231. PMID: 9211849.
  4. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16. PMID: 20525256. DOI: 10.1186/1750-1172-5-16.
  5. Patterson MC, Mengel E, Wijburg FA, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis. 2013;8:12. PMID: 23324478. DOI: 10.1186/1750-1172-8-12.
  6. Geberhiwot T, Moro A, Dardis A, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;13(1):50. PMID: 29609637. DOI: 10.1186/s13023-018-0785-7.
  7. Wasserstein MP, Diaz GA, Lachmann RH, et al. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD) in adults and children: a randomized controlled trial. J Inherit Metab Dis. 2021;44(4):935-944. PMID: 33421179. DOI: 10.1002/jimd.12370.
  8. Mengel E, Klünemann HH, Lourenço CM, et al. Niemann-Pick disease type C symptomatology: an expert-based clinical description. Orphanet J Rare Dis. 2013;8:166. PMID: 24135395. DOI: 10.1186/1750-1172-8-166.
  9. Pineda M, Walterfang M, Patterson MC. Miglustat in Niemann-Pick disease type C patients: a systematic review. Orphanet J Rare Dis. 2018;13(1):140. PMID: 30111331. DOI: 10.1186/s13023-018-0844-0.
  10. Boenzi S, Deodato F. An overview on oxysterols as biomarkers in inborn errors of cholesterol metabolism and in other diseases. J Clin Med. 2016;5(12):113. PMID: 27916879. DOI: 10.3390/jcm5120113.